Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004196006> ?p ?o ?g. }
- W2004196006 endingPage "672" @default.
- W2004196006 startingPage "661" @default.
- W2004196006 abstract "Three anti-vascular endothelial growth factor (VEGF) therapies are currently used for the treatment of patients with wet age-related macular degeneration (AMD): pegaptanib, ranibizumab, and bevacizumab. Ranibizumab is an antibody fragment approved for the treatment of wet AMD. Bevacizumab is a full-length antibody registered for use in oncology but unlicensed for wet AMD. However, it is used off-label worldwide not only for wet AMD but also for various other ocular diseases associated with macular edema and abnormal vessel growth. We consider aspects of ranibizumab and bevacizumab in relation to their molecular characteristics, in vitro and in vivo properties, and preclinical safety data. Before 2009, most studies described the short-term toxicity of bevacizumab in multiple cell types of the eye. Since 2009, an increasing number of studies have compared the properties of ranibizumab and bevacizumab and investigated their impact on retinal cell functioning. Compared with bevacizumab, ranibizumab neutralizes VEGF better at low concentrations, maintains efficacy for longer, and has a higher retinal penetration and potency. Studies in animals demonstrate ranibizumab to be better localized to the injected eye, whereas bevacizumab appears to have a greater effect in the fellow eye. In humans, a localized and systemic effect has been reported for both molecules. In conclusion, overlapping yet distinct pharmacological properties of ranibizumab and bevacizumab indicate that safety or efficacy data from one cannot be extrapolated to the other." @default.
- W2004196006 created "2016-06-24" @default.
- W2004196006 creator A5016922490 @default.
- W2004196006 creator A5089030421 @default.
- W2004196006 date "2011-04-01" @default.
- W2004196006 modified "2023-10-13" @default.
- W2004196006 title "Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab" @default.
- W2004196006 cites W1539571840 @default.
- W2004196006 cites W1588491549 @default.
- W2004196006 cites W1802218256 @default.
- W2004196006 cites W1965259073 @default.
- W2004196006 cites W1966486839 @default.
- W2004196006 cites W1970554379 @default.
- W2004196006 cites W1972242350 @default.
- W2004196006 cites W1973281481 @default.
- W2004196006 cites W1974537848 @default.
- W2004196006 cites W1985648029 @default.
- W2004196006 cites W1985695422 @default.
- W2004196006 cites W1987062912 @default.
- W2004196006 cites W1987699263 @default.
- W2004196006 cites W1992528831 @default.
- W2004196006 cites W1995044506 @default.
- W2004196006 cites W1999053742 @default.
- W2004196006 cites W2002101142 @default.
- W2004196006 cites W2002637725 @default.
- W2004196006 cites W2004504155 @default.
- W2004196006 cites W2007317284 @default.
- W2004196006 cites W2012906786 @default.
- W2004196006 cites W2012964196 @default.
- W2004196006 cites W2013306405 @default.
- W2004196006 cites W2014260690 @default.
- W2004196006 cites W2020252056 @default.
- W2004196006 cites W2020761135 @default.
- W2004196006 cites W2023400025 @default.
- W2004196006 cites W2026686158 @default.
- W2004196006 cites W2027359865 @default.
- W2004196006 cites W2027538443 @default.
- W2004196006 cites W2028031291 @default.
- W2004196006 cites W2031531075 @default.
- W2004196006 cites W2034029819 @default.
- W2004196006 cites W2034383440 @default.
- W2004196006 cites W2037623358 @default.
- W2004196006 cites W2041071253 @default.
- W2004196006 cites W2041611183 @default.
- W2004196006 cites W2043557241 @default.
- W2004196006 cites W2044283334 @default.
- W2004196006 cites W2047439094 @default.
- W2004196006 cites W2051149451 @default.
- W2004196006 cites W2053438140 @default.
- W2004196006 cites W2060385365 @default.
- W2004196006 cites W2062756251 @default.
- W2004196006 cites W2068742492 @default.
- W2004196006 cites W2069070941 @default.
- W2004196006 cites W2069079852 @default.
- W2004196006 cites W2069826874 @default.
- W2004196006 cites W2070205845 @default.
- W2004196006 cites W2072011053 @default.
- W2004196006 cites W2073434314 @default.
- W2004196006 cites W2073500557 @default.
- W2004196006 cites W2073888700 @default.
- W2004196006 cites W2077022482 @default.
- W2004196006 cites W2085712747 @default.
- W2004196006 cites W2088562953 @default.
- W2004196006 cites W2088713243 @default.
- W2004196006 cites W2091042111 @default.
- W2004196006 cites W2091407629 @default.
- W2004196006 cites W2091597300 @default.
- W2004196006 cites W2091929661 @default.
- W2004196006 cites W2091989599 @default.
- W2004196006 cites W2095251825 @default.
- W2004196006 cites W2097423690 @default.
- W2004196006 cites W2101212248 @default.
- W2004196006 cites W2118288927 @default.
- W2004196006 cites W2118873152 @default.
- W2004196006 cites W2121109442 @default.
- W2004196006 cites W2124415048 @default.
- W2004196006 cites W2139906402 @default.
- W2004196006 cites W2141276024 @default.
- W2004196006 cites W2141737497 @default.
- W2004196006 cites W2142693543 @default.
- W2004196006 cites W2153632706 @default.
- W2004196006 cites W2154770697 @default.
- W2004196006 cites W2163685069 @default.
- W2004196006 cites W2163886094 @default.
- W2004196006 cites W2164361482 @default.
- W2004196006 cites W2330906582 @default.
- W2004196006 cites W2915852396 @default.
- W2004196006 cites W4243881150 @default.
- W2004196006 cites W4256101427 @default.
- W2004196006 doi "https://doi.org/10.1038/eye.2011.66" @default.
- W2004196006 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3178135" @default.
- W2004196006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21455242" @default.
- W2004196006 hasPublicationYear "2011" @default.
- W2004196006 type Work @default.
- W2004196006 sameAs 2004196006 @default.
- W2004196006 citedByCount "112" @default.
- W2004196006 countsByYear W20041960062012 @default.
- W2004196006 countsByYear W20041960062013 @default.